Author:
Buzzai Anthony C.,Wagner Teagan,Audsley Katherine M.,Newnes Hannah V.,Barrett Lucy W.,Barnes Samantha,Wylie Ben C.,Stone Shane,McDonnell Alison,Fear Vanessa S.,Foley Bree,Waithman Jason
Funder
National Health and Medical Research Council
Cancer Australia
Cure Cancer Australia Foundation
Subject
Immunology,Immunology and Allergy
Reference44 articles.
1. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy;Rosenberg;Clin Cancer Res,2011
2. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma238997
GoffSL
DudleyME
CitrinDE
SomervilleRP
WunderlichJR
DanforthDN
10.1200/JCO.2016.66.722027217459J Clin Oncol342016
3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;New Engl J Med,2015
4. T cell exclusion, immune privilege, and the tumor microenvironment;Joyce;Science.,2015
5. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation;Bald;Cancer Discov,2014
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献